Company Profile

ImmunoMedics Inc
Profile last edited on: 10/11/22      CAGE: 1TSG0      UEI: S4NHH3294XM6

Business Identifier: MAb-based treatments for cancer and autoimmune diseases
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

300 The American Road
Morris Plains, NJ 07950
   (973) 605-8200
Location: Single
Congr. District: 11
County: Morris

Public Profile

In October 2020, it was announced that Gilead Sciences - itself an SBIR involved firm in the firm's early days - had completed acquire Immunomedics, Inc. (Nasdaq: IMMU) for a sum of approximately $21 billion in the aggregate. A leader in next-generation antibody-drug conjugate (ADC) technology, Immunomedics is a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, the firm ceasedtrading that day. ImmunoMedics Inc had developed a number of advanced technologies allowing creatiion of humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create targeted agents. ImmunoMedics has licensed its product candidate epratuzumab, to UCB S.A. (UCB), for the treatment of all autoimmune disease indications. Epratuzumab’s advanced clinical testing is for the treatment of systemic lupus erythematosus (SLE), and in non-Hodgkin’s lymphoma (NHL). Rights have been retained for epratuzumab in oncology indications, subject to UCB’s buy-in option, and is advancing trials in lymphoma and in childhood acute lymphoblastic leukemia (ALL), in cooperation with National Cancer Institute Study G

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Cynthia L Sullivan -- President

  Kurt Andrews -- Chief Human Resource Officer

  Thomas M Cardillo

  Chien Hsing K Chang

  Brendan Delaney -- CCO

  David M Goldenberg -- Founder, Chief Scientific Officer and Chief Medical Officer

  Serengulam V Govindan

  Gary L Griffiths

  Hans Hansen

  Habibe Karacay

  Shui-On Leung

  Donglin Liu

  William McBride

  Peter Pfreundschuh -- Vice President, Finance and Chief Financial Officer

  Zhengxing Qu

  Edmund A Rossi

  Puja Sapra

  Lisa B Shih

  Dan Shochat

  Robert M Sundoro

  William A Wegener